Literature DB >> 29995559

Mitochondria-targeted antioxidant SkQ1 suppresses fibrosarcoma and rhabdomyosarcoma tumour cell growth.

Ekaterina Titova1, Galina Shagieva1, Olga Ivanova1, Lidiya Domnina1, Maria Domninskaya1, Olga Strelkova1, Natalya Khromova2, Pavel Kopnin2, Boris Chernyak1, Vladimir Skulachev1,3, Vera Dugina1.   

Abstract

Mitochondria are important regulators of tumour growth and progression due to their specific role in cancer metabolism and modulation of apoptotic pathways. In this paper we describe that mitochondria-targeted antioxidant SkQ1 designed as a conjugate of decyl-triphenylphosphonium cation (TPP+) with plastoquinone, suppressed the growth of fibrosarcoma HT1080 and rhabdomyosarcoma RD tumour cells in culture and tumour growth of RD in xenograft nude mouse model. Under the same conditions, no detrimental effect of SkQ1 on cell growth of primary human subcutaneous fibroblasts was observed. The tumour growth suppression was shown to be a result of the antioxidant action of low nanomolar concentrations of SkQ1. We have revealed significant prolongation of mitosis induced by SkQ1 in both tumour cell cultures. Prolonged mitosis and apoptosis could be responsible for growth suppression after SkQ1 treatment in RD cells. Growth suppression in HT1080 cells was accompanied by the delay of telophase and cytokinesis, followed by multinuclear cells formation. The effects of SkQ1 on the cell cycle were proved to be at least partially mediated by inactivation of Aurora family kinases. ABBREVIATIONS: TPP+: Triphenylphosphonium cation; ROS: Reactive oxygen species; mtROS: Mitochondrial reactive oxygen species; NAC: N-acetyl-L-cysteine; DCFH-DA: Dichlorodihydrofluorescein diacetate; APC: Anaphase promoting complex; ABPs: Actin-binding proteins; DMEM: Dulbecco's modified Eagle media; SDS: sodium dodecyl sulfate; HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.

Entities:  

Keywords:  Aurora family kinases; Mitochondrial reactive oxygen species; SkQ1; mitochondria-targeted antioxidant

Mesh:

Substances:

Year:  2018        PMID: 29995559      PMCID: PMC6133338          DOI: 10.1080/15384101.2018.1496748

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  41 in total

1.  ROS up-regulation mediates Ras-induced changes of cell morphology and motility.

Authors:  Antonina Y Alexandrova; Pavel B Kopnin; Jury M Vasiliev; Boris P Kopnin
Journal:  Exp Cell Res       Date:  2006-04-19       Impact factor: 3.905

2.  Beta and gamma-cytoplasmic actins display distinct distribution and functional diversity.

Authors:  Vera Dugina; Ingrid Zwaenepoel; Giulio Gabbiani; Sophie Clément; Christine Chaponnier
Journal:  J Cell Sci       Date:  2009-07-28       Impact factor: 5.285

Review 3.  Mitotic catastrophe: a mechanism for avoiding genomic instability.

Authors:  Ilio Vitale; Lorenzo Galluzzi; Maria Castedo; Guido Kroemer
Journal:  Nat Rev Mol Cell Biol       Date:  2011-04-29       Impact factor: 94.444

4.  Scavenging of reactive oxygen species in mitochondria induces myofibroblast differentiation.

Authors:  Ekaterina N Popova; Olga Y Pletjushkina; Vera B Dugina; Lidia V Domnina; Olga Y Ivanova; Denis S Izyumov; Vladimir P Skulachev; Boris V Chernyak
Journal:  Antioxid Redox Signal       Date:  2010-11-01       Impact factor: 8.401

Review 5.  Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?

Authors:  Simran S Sabharwal; Paul T Schumacker
Journal:  Nat Rev Cancer       Date:  2014-11       Impact factor: 60.716

Review 6.  Mitochondria-Targeted Agents: Mitochondriotropics, Mitochondriotoxics, and Mitocans.

Authors:  Diana Guzman-Villanueva; Volkmar Weissig
Journal:  Handb Exp Pharmacol       Date:  2017

7.  Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit.

Authors:  Laurie E Littlepage; Joan V Ruderman
Journal:  Genes Dev       Date:  2002-09-01       Impact factor: 11.361

8.  Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.

Authors:  Christopher P Gully; Fanmao Zhang; Jian Chen; James A Yeung; Guermarie Velazquez-Torres; Edward Wang; Sai-Ching Jim Yeung; Mong-Hong Lee
Journal:  Mol Cancer       Date:  2010-02-22       Impact factor: 27.401

Review 9.  In search of novel highly active mitochondria-targeted antioxidants: thymoquinone and its cationic derivatives.

Authors:  Inna I Severina; Fedor F Severin; Galina A Korshunova; Natalya V Sumbatyan; Tatyana M Ilyasova; Ruben A Simonyan; Anton G Rogov; Tatyana A Trendeleva; Renata A Zvyagilskaya; Vera B Dugina; Lidia V Domnina; Elena K Fetisova; Konstantin G Lyamzaev; Mikhail Yu Vyssokikh; Boris V Chernyak; Maxim V Skulachev; Vladimir P Skulachev; Viktor A Sadovnichii
Journal:  FEBS Lett       Date:  2013-05-10       Impact factor: 4.124

Review 10.  Mitochondria as signaling organelles.

Authors:  Navdeep S Chandel
Journal:  BMC Biol       Date:  2014-05-27       Impact factor: 7.431

View more
  8 in total

1.  Novel Soloxolone Amides as Potent Anti-Glioblastoma Candidates: Design, Synthesis, In Silico Analysis and Biological Activities In Vitro and In Vivo.

Authors:  Andrey V Markov; Anna A Ilyina; Oksana V Salomatina; Aleksandra V Sen'kova; Alina A Okhina; Artem D Rogachev; Nariman F Salakhutdinov; Marina A Zenkova
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-14

Review 2.  Targeting Energy Metabolism in Cancer Treatment.

Authors:  Joanna Kubik; Ewelina Humeniuk; Grzegorz Adamczuk; Barbara Madej-Czerwonka; Agnieszka Korga-Plewko
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

Review 3.  Mitochondria as a Novel Target for Cancer Chemoprevention: Emergence of Mitochondrial-targeting Agents.

Authors:  Mofei Huang; Charles R Myers; Yian Wang; Ming You
Journal:  Cancer Prev Res (Phila)       Date:  2020-12-10

Review 4.  Coenzyme Q10 Analogues: Benefits and Challenges for Therapeutics.

Authors:  Juan M Suárez-Rivero; Carmen J Pastor-Maldonado; Suleva Povea-Cabello; Mónica Álvarez-Córdoba; Irene Villalón-García; Manuel Munuera-Cabeza; Alejandra Suárez-Carrillo; Marta Talaverón-Rey; José A Sánchez-Alcázar
Journal:  Antioxidants (Basel)       Date:  2021-02-04

Review 5.  Mitochondria-Targeted Antioxidants: A Step towards Disease Treatment.

Authors:  Qian Jiang; Jie Yin; Jiashun Chen; Xiaokang Ma; Miaomiao Wu; Gang Liu; Kang Yao; Bie Tan; Yulong Yin
Journal:  Oxid Med Cell Longev       Date:  2020-12-03       Impact factor: 6.543

6.  Mitochondrial targeted antioxidants, mitoquinone and SKQ1, not vitamin C, mitigate doxorubicin-induced damage in H9c2 myoblast: pretreatment vs. co-treatment.

Authors:  Brian Sacks; Halil Onal; Rose Martorana; Amogh Sehgal; Amanda Harvey; Catherine Wastella; Hafsa Ahmad; Erin Ross; Adona Pjetergjoka; Sachin Prasad; Robert Barsotti; Lindon H Young; Qian Chen
Journal:  BMC Pharmacol Toxicol       Date:  2021-09-16       Impact factor: 2.483

Review 7.  Metabolic landscapes in sarcomas.

Authors:  Richard Miallot; Franck Galland; Virginie Millet; Jean-Yves Blay; Philippe Naquet
Journal:  J Hematol Oncol       Date:  2021-07-22       Impact factor: 17.388

Review 8.  Genetics, epigenetics and redox homeostasis in rhabdomyosarcoma: Emerging targets and therapeutics.

Authors:  Ananya Pal; Hsin Yao Chiu; Reshma Taneja
Journal:  Redox Biol       Date:  2019-01-25       Impact factor: 11.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.